MX2017007067A - Administracion de un inhibidor selectivo de la trans-señalizacion de il-6. - Google Patents
Administracion de un inhibidor selectivo de la trans-señalizacion de il-6.Info
- Publication number
- MX2017007067A MX2017007067A MX2017007067A MX2017007067A MX2017007067A MX 2017007067 A MX2017007067 A MX 2017007067A MX 2017007067 A MX2017007067 A MX 2017007067A MX 2017007067 A MX2017007067 A MX 2017007067A MX 2017007067 A MX2017007067 A MX 2017007067A
- Authority
- MX
- Mexico
- Prior art keywords
- trans
- inhibitor
- selective
- administration
- signalling inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
Abstract
Un inhibidor selectivo de la trans-señalización de IL-6 se puede usar para tratar una variedad de condiciones mediadas por la IL-6, entre ellas, enfermedades inflamatorias y cáncer. El inhibidor se puede administrar de forma segura a los seres humanos en una variedad de dosis. Además, el inhibidor atenúa los efectos perjudiciales asociados con otros inhibidores de IL-6, tales como la disminución en los recuentos de neutrófilos, los recuentos de plaquetas y los niveles de proteína C reactiva.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462086054P | 2014-12-01 | 2014-12-01 | |
PCT/IB2015/002459 WO2016087941A1 (en) | 2014-12-01 | 2015-12-01 | Administration of a selective il-6-trans-signalling inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017007067A true MX2017007067A (es) | 2018-04-30 |
Family
ID=55305021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017007067A MX2017007067A (es) | 2014-12-01 | 2015-12-01 | Administracion de un inhibidor selectivo de la trans-señalizacion de il-6. |
Country Status (19)
Country | Link |
---|---|
US (2) | US11198721B2 (es) |
EP (2) | EP3912636A1 (es) |
JP (1) | JP6775513B2 (es) |
KR (1) | KR20170135819A (es) |
CN (1) | CN107223132A (es) |
CA (1) | CA2969301A1 (es) |
DK (1) | DK3226888T3 (es) |
ES (1) | ES2875351T3 (es) |
HR (1) | HRP20210737T1 (es) |
HU (1) | HUE054742T2 (es) |
LT (1) | LT3226888T (es) |
MA (2) | MA54761A (es) |
MD (1) | MD3226888T2 (es) |
MX (1) | MX2017007067A (es) |
PL (1) | PL3226888T3 (es) |
PT (1) | PT3226888T (es) |
RS (1) | RS61947B1 (es) |
SI (1) | SI3226888T1 (es) |
WO (1) | WO2016087941A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA41116A (fr) | 2014-12-01 | 2017-10-10 | Ferring Bv | Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif |
CN115867345A (zh) * | 2020-06-10 | 2023-03-28 | 辉凌有限公司 | 用于治疗动脉粥样硬化性心血管疾病的药物化合物 |
WO2022139580A1 (en) | 2020-12-22 | 2022-06-30 | Ferring B.V. | Blood gene expression biomarkers to predict response in patients with inflammatory bowel diseases |
WO2024011946A1 (en) * | 2022-07-12 | 2024-01-18 | I-Mab Biopharma (Hangzhou) Co., Ltd | Polypeptide dimers for the treatment of systemic sclerosis |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US5783672A (en) | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
DE19941897B4 (de) | 1999-09-02 | 2006-06-14 | GSF - Forschungszentrum für Umwelt und Gesundheit GmbH | IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen |
CA2399832C (en) | 2000-02-11 | 2011-09-20 | Stephen D. Gillies | Enhancing the circulating half-life of antibody-based fusion proteins |
ATE382636T1 (de) * | 2000-04-21 | 2008-01-15 | Conaris Res Inst Ag | Fusionsproteine, die zwei lösliche gp130 moleküle enthalten |
AU2002303869B2 (en) | 2001-05-21 | 2007-08-16 | Novartis Ag | Pulmonary administration of chemically modified insulin |
EP1406929A2 (en) | 2001-07-18 | 2004-04-14 | MERCK PATENT GmbH | Glycoprotein vi fusion proteins |
AU2002356511A1 (en) | 2001-07-30 | 2003-04-01 | Immunex Corporation | T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using |
JP2004182638A (ja) | 2002-12-03 | 2004-07-02 | Yakult Honsha Co Ltd | 炎症性疾患又は悪性腫瘍の予防治療剤 |
EP1491554A1 (en) | 2003-06-23 | 2004-12-29 | CONARIS research institute AG | PEGylated soluble gp130-dimers useful as a medicament |
DE602004014758D1 (de) | 2004-08-27 | 2008-08-14 | Conaris Res Inst Ag | Optimierte Nukleotidsequenzen die für sgp130 kodieren |
EP1801121A1 (en) | 2005-12-23 | 2007-06-27 | CONARIS research institute AG | Soluble gp130 molecule variants useful as a medicament |
KR20080090484A (ko) * | 2005-12-30 | 2008-10-08 | 메르크 파텐트 게엠베하 | GP130 에 대한, IL-6Rα 와 복합체를 형성한 IL-6의 결합을 방해하는 항-IL-6 항체 |
ATE480568T1 (de) * | 2006-06-30 | 2010-09-15 | Conaris Res Inst Ag | Verbesserte sgp 130fc dimere |
EP2050759A1 (en) | 2007-10-19 | 2009-04-22 | CONARIS research institute AG | Soluble gp 130 muteins with improved binding activity |
MX2013006234A (es) | 2011-01-06 | 2013-08-01 | Univ Johns Hopkins | Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero. |
MA41116A (fr) | 2014-12-01 | 2017-10-10 | Ferring Bv | Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif |
-
2015
- 2015-12-01 JP JP2017547084A patent/JP6775513B2/ja active Active
- 2015-12-01 PL PL15832692T patent/PL3226888T3/pl unknown
- 2015-12-01 PT PT158326926T patent/PT3226888T/pt unknown
- 2015-12-01 CN CN201580075096.0A patent/CN107223132A/zh active Pending
- 2015-12-01 MD MDE20170156T patent/MD3226888T2/ro unknown
- 2015-12-01 SI SI201531602T patent/SI3226888T1/sl unknown
- 2015-12-01 EP EP21162245.1A patent/EP3912636A1/en active Pending
- 2015-12-01 RS RS20210709A patent/RS61947B1/sr unknown
- 2015-12-01 DK DK15832692.6T patent/DK3226888T3/da active
- 2015-12-01 US US15/532,092 patent/US11198721B2/en active Active
- 2015-12-01 WO PCT/IB2015/002459 patent/WO2016087941A1/en active Application Filing
- 2015-12-01 KR KR1020177018155A patent/KR20170135819A/ko not_active IP Right Cessation
- 2015-12-01 HU HUE15832692A patent/HUE054742T2/hu unknown
- 2015-12-01 EP EP15832692.6A patent/EP3226888B1/en active Active
- 2015-12-01 ES ES15832692T patent/ES2875351T3/es active Active
- 2015-12-01 LT LTEP15832692.6T patent/LT3226888T/lt unknown
- 2015-12-01 CA CA2969301A patent/CA2969301A1/en active Pending
- 2015-12-01 MX MX2017007067A patent/MX2017007067A/es unknown
- 2015-12-01 MA MA054761A patent/MA54761A/fr unknown
- 2015-12-01 MA MA41114A patent/MA41114B1/fr unknown
-
2021
- 2021-05-11 HR HRP20210737TT patent/HRP20210737T1/hr unknown
- 2021-11-09 US US17/522,320 patent/US20220135652A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170320932A1 (en) | 2017-11-09 |
CN107223132A (zh) | 2017-09-29 |
SI3226888T1 (sl) | 2021-08-31 |
DK3226888T3 (da) | 2021-07-12 |
EP3226888A1 (en) | 2017-10-11 |
WO2016087941A1 (en) | 2016-06-09 |
HRP20210737T1 (hr) | 2021-06-11 |
US20220135652A1 (en) | 2022-05-05 |
EP3912636A1 (en) | 2021-11-24 |
LT3226888T (lt) | 2021-05-25 |
RS61947B1 (sr) | 2021-07-30 |
ES2875351T3 (es) | 2021-11-10 |
PT3226888T (pt) | 2021-06-02 |
MA41114B1 (fr) | 2021-06-30 |
JP2017537155A (ja) | 2017-12-14 |
PL3226888T3 (pl) | 2021-11-02 |
CA2969301A1 (en) | 2016-06-09 |
MD3226888T2 (ro) | 2021-08-31 |
HUE054742T2 (hu) | 2021-09-28 |
KR20170135819A (ko) | 2017-12-08 |
EP3226888B1 (en) | 2021-04-21 |
MA54761A (fr) | 2021-11-24 |
JP6775513B2 (ja) | 2020-10-28 |
US11198721B2 (en) | 2021-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
MX2018006578A (es) | Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias. | |
NZ730865A (en) | Peptides having anti-inflammatory properties | |
NZ742819A (en) | Inhibitors of cxcr2 | |
MX2021007899A (es) | Composiciones con inhibidor selectivo de la trans-se?alizacion de il-6. | |
NZ724691A (en) | Quinoline derivatives as smo inhibitors | |
EA201791133A1 (ru) | Ингибиторы erk | |
MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
PH12015502698A1 (en) | Dual selective pi3 delta and gamma kinase inhibitors | |
SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
MX2015009058A (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
EA201791293A1 (ru) | Сайт-специфическое дозирование ингибитора btk | |
EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
PH12016502530A1 (en) | Pharmaceutical compositions comprising dgla and use of same | |
MX2017007067A (es) | Administracion de un inhibidor selectivo de la trans-señalizacion de il-6. | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
EA031679B9 (ru) | Производные тетрагидрохинолина в качестве ингибиторов бромодомена | |
EA201791294A1 (ru) | 7-(МОРФОЛИНИЛ)-2-(N-ПИПЕРАЗИНИЛ)МЕТИЛТИЕНО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
MX2023003924A (es) | Metodos de administracion de tratamiento antifibrotico. | |
EP3151826A4 (en) | Omega-3 compositions, dosage forms, and methods of use | |
SG11202006601VA (en) | Methods of treating chronic inflammatory diseases | |
PH12020500472A1 (en) | Autotaxin inhibitor compounds |